IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of Mangiardi et al. Confirmation No. 4712 Application No. 10/585,430 Filed: January 7, 2009 For: IMPLANTABLE DEVICE DELIVERY SYSTEM HANDLE AND METHOD **OF USE** Group Art Unit: 3734 Examiner: Brian J. Graham Attorney Docket No. 37621/51001 Date: July 14, 2010 **INFORMATION DISCLOSURE STATEMENT** TO THE COMMISSIONER FOR PATENTS: 1. Pursuant to the duty of disclosure, documents listed on the accompanying Form PTO-1449 (or equivalent) are presented for the Examiner's consideration. X Copies of listed U.S. patents and U.S. patent application publications are not required for submission. (37 C.F.R. § 1.98(a)(2)(ii)) \boxtimes Copies of listed foreign patent documents and/or non-patent literature are enclosed. (37 C.F.R. § 1.98(a)(2)) Copies of the documents listed at (sheet/cite no.) of the attached Form PTO-1449 (or equivalent) are omitted because (1) they are already of record in U.S. Patent Application No. ______, filed _____, on which this application relies for an earlier filing date under 35 U.S.C. § 120; and (2) any information disclosure statement filed in the prosecution of Application No. , complies with 37 CFR §§ 1.98(a) through (c). (37 C.F.R. § 1.98(d)) A copy of copending U.S. Patent Application No. ______, filed , for _____, listed at (sheet/cite no.) ____ of the attached Form PTO-1449 (or equivalent), ___ is enclosed / ___ is omitted. (Copy not required if available via 1FW. 1287 OG 163 (Oct. 19, 2004).).

This information disclosure statement is being submitted (check box a., b., or c.):

Within three months of the filing date of a national application or entry of

the national stage in an international application; or before the mailing of a

a.

2.

			first Office action on the merits; or before the mailing of a first Office action after the filing of a request for continued examination under 37 CFR 1.114. (No statement under 37 CFR 1.97(e) is required.); or
	b.	\boxtimes	After the period set forth in paragraph 2a, but before the mailing date of either a final action, a notice of allowance, or an action that otherwise closes prosecution in the application. (Check box i. or ii.)
		i.	The \$180.00 information disclosure statement submission fee set forth in 37 CFR 1.17(p) is paid herewith, or
		ii.	A statement specified by 37 CFR 1.97(e) is set forth below; or
	c.		After the mailing date of a final action or notice of allowance and on or before payment of the issue fee. A statement specified by 37 CFR 1.97(e) is set forth below. Enclosed is the \$180.00 information disclosure statement processing fee set forth in 37 CFR 1.17(p).
Fee Payment			
	a.		A check in the amount of \$ is enclosed.
	b.	\boxtimes	Payment by credit card.
	c.		Please charge our Deposit Account No. 502375 in the amount of \$
	d.		The Commissioner is hereby authorized to charge any additional fees which may be required in connection with filing of these papers, or credit overpayment to Deposit Account No. 502375.
If a statement specified by 37 CFR 1.97(e) is required, the attorney or agent signing below hereby states that:			
		first ci	em of information contained in this information disclosure statement was ted in any communication from a foreign patent office in a counterpart application not more than three months prior to the filing of the lation disclosure statement; or
		cited in applica making disclos	n of information contained in this information disclosure statement was a communication from a foreign patent office in a counterpart foreign ation, and, to the knowledge of the person signing the certification after g reasonable inquiry, no item of information contained in this information sure statement was known to any individual designated in 37 CFR 1.56(c) than three months prior to the filing of the information disclosure statement.

2

3.

4.

5.	A concise explanation of the relevance of each document not in the English language and/or selected documents in the English language is set forth below
	Respectfully submitted,
	Merit Medical Systems, Inc.
	By Well Belliu Matthew S. Bethards
	Registration No. 51,466

STOEL RIVES LLP One Utah Center Suite 1100 201 S Main Street Salt Lake City, UT 84111-4904 Telephone: (801) 328-3131 Facsimile: (801) 578-6999